An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non–small-cell lung cancer.
Original Article: Osimertinib Improves Patient-Reported Outcomes in Advanced NSCLC